Restrepo Lucas, Bang Oh Young, Ovbiagele Bruce, Ali Latisha, Kim Doojin, Liebeskind David S, Starkman Sidney, Vinuela Fernando, Duckwiler Gary R, Jahan Reza, Saver Jeffrey L
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA.
Cerebrovasc Dis. 2009;28(4):384-90. doi: 10.1159/000235625. Epub 2009 Aug 22.
Endovascular recanalization therapies are an increasingly employed treatment strategy in acute cerebral ischemia. The determinants of the final clinical outcome after endovascular treatment have been understudied. We investigated the effects of hyperlipidemia and statins on acute ischemic stroke outcomes after endovascular procedures.
An inquiry of a prospectively maintained stroke registry was conducted. Endovascular procedures were performed using recombinant tissue plasminogen activator, prourokinase or the Merci device within 12 hours after symptom onset. The analyzed outcomes were revascularization, hemorrhage and excellent functional outcome (Rankin score of 0-1 at 3 months). The analyses included chi(2) and Wilcoxon rank sum, logistic regression (for multivariate analyses with binary outcomes) and linear regression (for continuous outcomes). Significance was set at p < 0.05.
We included 142 patients, 80% treated with intra-arterial fibrinolysis, 22% with percutaneous mechanical embolectomy and 27% treated with intravenous fibrinolysis prior to endovascular intervention. Age (OR = 0.956, 95% CI = 0.927-0.986, p = 0.0041), National Institutes of Health Stroke Scale (NIHSS) score on admission (OR = 0.881, 95% CI = 0.812-0.957, p = 0.0025) and history of hyperlipidemia (OR = 0.284, 95% CI = 0.08-0.99, p = 0.0478) were negatively associated with excellent functional outcome at 3 months. Every 50 mg/dl increment in the total cholesterol level resulted in 64% decrease in the odds of excellent functional outcome (OR = 0.36, 95% CI = 0.447-0.882, p = 0.0253). History of hyperlipidemia decreased the likelihood of neurological improvement (p = 0.0462) and was associated with a higher NIHSS score at 7 days or discharge. Statin use was related to an average 6.5-unit NIHSS decrease at discharge (p = 0.0168). Statins were not associated with increased frequency of recanalization or symptomatic intracerebral hemorrhage.
History of hyperlipidemia may have a negative impact on the outcomes of acute ischemic stroke treated with intra-arterial fibrinolysis or percutaneous mechanical embolectomy. Statin use before and after these procedures may be related to better neurological outcomes. Larger prospective studies are needed to endorse these findings.
血管内再通治疗在急性脑缺血中越来越多地被采用。血管内治疗后最终临床结局的决定因素尚未得到充分研究。我们调查了高脂血症和他汀类药物对血管内治疗后急性缺血性卒中结局的影响。
对前瞻性维护的卒中登记册进行查询。在症状发作后12小时内使用重组组织型纤溶酶原激活剂、尿激酶原或Merci装置进行血管内治疗。分析的结局包括再通、出血和良好的功能结局(3个月时Rankin评分为0-1)。分析包括卡方检验和Wilcoxon秩和检验、逻辑回归(用于二元结局的多变量分析)和线性回归(用于连续结局)。显著性设定为p<0.05。
我们纳入了142例患者,80%接受动脉内溶栓治疗,22%接受经皮机械取栓治疗,27%在血管内介入治疗前接受静脉溶栓治疗。年龄(OR=0.956,95%CI=0.927-0.986,p=0.0041)、入院时美国国立卫生研究院卒中量表(NIHSS)评分(OR=0.881,95%CI=0.812-0.957,p=0.0025)和高脂血症病史(OR=0.284,95%CI=0.08-0.99,p=0.0478)与3个月时良好的功能结局呈负相关。总胆固醇水平每增加50mg/dl,良好功能结局的几率降低64%(OR=0.36,9